Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSasadeusz, Joe-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorHughes, Peter D-
dc.contributor.authorLee Lim, Seng-
dc.contributor.authorLucas, Michaela-
dc.contributor.authorMcColl, Geoff-
dc.contributor.authorMcLachlan, Sue Anne-
dc.contributor.authorPeters, Marion G-
dc.contributor.authorShackel, Nicholas-
dc.contributor.authorSlavin, Monica-
dc.contributor.authorSundararajan, Vijaya-
dc.contributor.authorThompson, Alexander-
dc.contributor.authorDoyle, Joseph-
dc.contributor.authorRickard, James-
dc.contributor.authorDe Cruz, Peter-
dc.contributor.authorGish, Robert G-
dc.contributor.authorVisvanathan, Kumar-
dc.identifier.citationClinics in liver disease 2019; 23(3): 521-534-
dc.description.abstractBecause of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.-
dc.subjectDirect-acting antivirals-
dc.subjectHepatitis B-
dc.subjectInflammatory bowel diseases-
dc.subjectRheumatoid arthritis-
dc.titleScreening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.-
dc.typeJournal Article-
dc.identifier.journaltitleClinics in liver disease-
dc.identifier.affiliationUniversity of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australiaen
dc.identifier.affiliationUniversity of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australiaen
dc.identifier.affiliationBurnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australiaen
dc.identifier.affiliationThe Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australiaen
dc.identifier.affiliationDepartment of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australiaen
dc.identifier.affiliationVictorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australiaen
dc.identifier.affiliationSt Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australiaen
dc.identifier.affiliationUniversity of Melbourne, Grattan Street, Parkville, Victoria 3010, Australiaen
dc.identifier.affiliationIngham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationPeter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australiaen
dc.identifier.affiliationRoyal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australiaen
dc.identifier.affiliationNational University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore-
dc.identifier.affiliationUniversity of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA-
dc.identifier.affiliationDivision of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA-
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australia-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.